Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Registration Number
- NCT05291663
- Lead Sponsor
- Assiut University
- Brief Summary
Evaluation of the efficacy of the accelerated radiotherapy in squamous cell carcinoma of head and neck
- Detailed Description
* HNSCC is the sixth most common cancer worldwide, with 890.000 new cases and 450.000 deaths in 2018.
* The incidence of HNSCC continues to rise and is anticipated to increase by 30% (that is, 1.08 million new cases annually) by 2030.
* Squamous cell carcinoma constitutes 90% of all head and neck cancers and it predominates in males.
* Risk factors such as cigarette consumption and alcohol consumption, are well established.
* Treatment decisions are guided by clinic-pathologic factors such as age and stage.
* Treatment of the majority of patients with HNSCC requires multimodality approaches.
* Radiotherapy or surgery alone can be considered as the standard treatment modality for patients having early head and neck squamous cell carcinoma.
* When conventionally fractionated radiotherapy is used, long-term tumor control can be achieved in less than 30% of patients with advanced head and neck carcinomas.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Patients of (18 up to 75 years of age)
- Performance status of 0-2 according to ECOG scale.
- Patients with no prior chemotherapy, radiotherapy or surgery except for biopsy.
- Patients with previous irradiation to head and neck.
- Pregnant or lactating women.
- Patients with impaired heart or lung diseases.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determine progression-free survival rate Baseline Determine the toxicity and loco-regional control by using accelerated RTH in squamous cell carcinoma in head and neck
- Secondary Outcome Measures
Name Time Method